Prognostic factors in patients with isolated recurrences of breast cancer (stage IV-NED)
- PMID: 10326787
- DOI: 10.1023/a:1006090319083
Prognostic factors in patients with isolated recurrences of breast cancer (stage IV-NED)
Abstract
Background: One to 10% of women with metastatic breast cancer have a recurrence of their disease as an isolated lesion (local, regional, or distant) which may be treated by surgical resection, irradiation, or both. These are patients with stage IV breast cancer with no evidence of disease, or stage IV-NED. Because natural history and prognostic factors for patients with stage IV-NED are poorly determined, we decided to evaluate a group of patients with stage IV-NED treated at a single institution.
Patients and methods: Ninety-six patients with isolated recurrence of stage IV breast cancer were analyzed retrospectively. Treatment of loco-regional or distant recurrence was surgery in 18 patients and surgery plus irradiation in 78 patients. Seventy-nine patients received systemic therapy after loco-regional treatment (24 chemotherapy and 55 hormonotherapy). Prognostic factors were analyzed and correlated with disease-free survival (DFS) and overall survival (OS).
Results: Five-year DFS and OS for the whole group were 29% and 49%, respectively. On the univariate analysis, patients without axillary nodal involvement at the time of mastectomy had significantly greater 5-year DFS and OS than patients with nodal involvement (51% vs. 14% and 70% vs. 34%, respectively, p < 0.05). DFS was also significantly better for patients receiving systemic therapy after local treatment (31% vs. 19%). On the multivariate analysis, absence of nodal involvement and systemic therapy were associated with longer DFS (p = 0.044 and p = 0.008, respectively) and OS (p = 0.009 and p = 0.011, respectively). None of the other factors analyzed including menopausal status, T-stage, number of involved nodes, receptor status, adjuvant therapy, sites of first recurrence, or time from mastectomy to first recurrence had a predictive value for DFS and OS.
Conclusion: Patients with stage IV-NED have poor prognosis due to early development of metastatic disease. Absence of axillary nodal involvement at the time of mastectomy and systemic therapy following local management is associated with improved DFS and OS. These results suggest that systemic therapy after local treatment in stage IV-NED is indicated. Poor prognosis in patients with previous nodal involvement warrants new approaches.
Similar articles
-
Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer with no evidence of disease.Breast J. 2002 Jan-Feb;8(1):2-9. doi: 10.1046/j.1524-4741.2002.08002.x. Breast J. 2002. PMID: 11856154 Clinical Trial.
-
Extracapsular axillary node extension in patients receiving adjuvant systemic therapy: an indication for radiotherapy?Int J Radiat Oncol Biol Phys. 1997 Jun 1;38(3):551-9. doi: 10.1016/s0360-3016(97)89483-7. Int J Radiat Oncol Biol Phys. 1997. PMID: 9231679
-
[Clinical characteristics and prognosis of patients with ipsilateral breast tumor recurrence after breast conservation therapy].Zhonghua Zhong Liu Za Zhi. 2018 May 23;40(5):352-358. doi: 10.3760/cma.j.issn.0253-3766.2018.05.007. Zhonghua Zhong Liu Za Zhi. 2018. PMID: 29860762 Chinese.
-
Possible clinical cure of metastatic breast cancer: lessons from our 30-year experience with oligometastatic breast cancer patients and literature review.Breast Cancer. 2012 Jul;19(3):218-37. doi: 10.1007/s12282-012-0347-0. Epub 2012 Apr 25. Breast Cancer. 2012. PMID: 22532161 Review.
-
Overview of resistance to systemic therapy in patients with breast cancer.Adv Exp Med Biol. 2007;608:1-22. doi: 10.1007/978-0-387-74039-3_1. Adv Exp Med Biol. 2007. PMID: 17993229 Review.
Cited by
-
Metastatic breast cancer in a Nigerian tertiary hospital.Afr Health Sci. 2011 Jun;11(2):279-84. Afr Health Sci. 2011. PMID: 21857862 Free PMC article.
MeSH terms
LinkOut - more resources
Medical